Neurocrine Biosciences, Inc. (NBIX)
167.40
-2.00
(-1.18%)
USD |
NASDAQ |
Nov 13, 16:00
167.38
-0.02
(-0.01%)
After-Hours: 19:59
Neurocrine Biosciences Gross Profit Margin (Quarterly) : 94.51% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 94.51% |
| June 30, 2026 | 95.87% |
| March 31, 2026 | 98.31% |
| December 31, 2025 | 97.82% |
| September 30, 2025 | 98.24% |
| June 30, 2025 | 98.36% |
| March 31, 2025 | 98.39% |
| December 31, 2024 | 97.53% |
| September 30, 2024 | 97.81% |
| June 30, 2024 | 97.36% |
| March 31, 2024 | 97.52% |
| December 31, 2023 | 97.40% |
| September 30, 2023 | 96.83% |
| June 30, 2023 | 96.53% |
| March 31, 2023 | 97.00% |
| December 31, 2022 | 97.18% |
| September 30, 2022 | 97.40% |
| June 30, 2022 | 97.70% |
| March 31, 2022 | 97.46% |
| December 31, 2021 | 97.72% |
| September 30, 2021 | 97.64% |
| June 30, 2021 | 98.03% |
| March 31, 2021 | 97.72% |
| December 31, 2020 | 97.94% |
| September 30, 2020 | 98.10% |
| Date | Value |
|---|---|
| June 30, 2020 | 98.51% |
| March 31, 2020 | 98.23% |
| December 31, 2019 | 98.12% |
| September 30, 2019 | 99.00% |
| June 30, 2019 | 98.64% |
| March 31, 2019 | 98.05% |
| December 31, 2018 | 98.83% |
| September 30, 2018 | 98.98% |
| June 30, 2018 | 98.66% |
| March 31, 2018 | 98.66% |
| December 31, 2017 | 99.20% |
| September 30, 2017 | 98.27% |
| June 30, 2017 | 89.74% |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | 0.00% |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | 0.00% |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Amgen, Inc. | 73.09% |
| BioCryst Pharmaceuticals, Inc. | 98.99% |
| Halozyme Therapeutics, Inc. | 77.28% |
| Iovance Biotherapeutics, Inc. | 52.64% |
| Precigen, Inc. | 90.79% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 20.38% |
| Return on Assets | 14.10% |
| Return on Invested Capital | 18.12% |
| Profit Margin (Quarterly) | 18.39% |
| Operating Margin (Quarterly) | 30.55% |
| Return on Net Operating Assets | 25.88% |